Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Arko Corp. (ARKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Arko Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Arko Corp. trades at $4.47 (market cap $493.06M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 10.3× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ARKO | |
|---|---|---|
Market Cap | $5.07B | $493.06M |
Sector | Health | Consumer Cyclical |
52-Week High | $29.45 | $8.64 |
52-Week Low | $20.06 | $3.82 |
Enterprise Value | $4.19B | $2.67B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
ARKO trades at $4.46, down 5.11% on the day, reflecting bearish technical signals and recent earnings miss. The company maintains a low P/S ratio of 0.06 and pays consistent dividends, but faces declining revenue and thin net margins. Recent news highlights weak Q2 2026 results and softer retail demand, with analysts holding a neutral stance.
Outlook remains cautious due to earnings volatility and competitive pressures, though the dividend yield and low valuation offer some value. Key risks include consumer spending sensitivity and high debt levels, requiring close monitoring of margin defense strategies and fuel pricing discipline for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
